We are live on ! Find out more
SCNI

Scinai Immunotherapeutics
SCNI

4 hedge funds and large institutions have $85.1K invested in Scinai Immunotherapeutics in 2024 Q4 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,100% more capital invested

Capital invested by funds: $7.09K → $85.1K (+$78K)

0% more ownership

Funds ownership: 0% → 0% (+0%)

20% less funds holding

Funds holding: 5 → 4 (-1)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
4
Holders Change
-1
Holders Change %
-20%
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$80.6K

Top Sellers

Rank Fund Capital Flow
1
APC
Aspire Private Capital
North Carolina
-$110
Name Holding Trade Value Shares
Change 		Change in
Stake
UBS Group
1
UBS Group
Switzerland
$78.6K +$80.6K +23,458 +78,193%
RhumbLine Advisers
2
RhumbLine Advisers
Massachusetts
$5.5K – – –
Morgan Stanley
3
Morgan Stanley
New York
$853 – – –
Credit Agricole
4
Credit Agricole
France
$140 – – –
APC
5
Aspire Private Capital
North Carolina
– -$110 -32 Closed

SCNI Hedge Fund Activity: Q4 2024 in Review

4 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in Scinai Immunotherapeutics (SCNI) for Q4 2024, worth a combined $85.1K — up 1,100% from $7.09K a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of SCNI and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 1 added.

The largest buyer was UBS Group, adding an estimated $80.6K. The largest seller was Aspire Private Capital, exiting entirely with an estimated $110 sold.

  • 4 institutional investors held Scinai Immunotherapeutics (SCNI) as of Q4 2024, down from 5 in Q3 2024.
  • Funds reported $85.1K of Scinai Immunotherapeutics stock for Q4 2024, up 1,100% quarter-over-quarter.
  • 0 funds opened new Scinai Immunotherapeutics positions in Q4 2024 and 1 closed out, a net change of -1 holder.
  • The largest Scinai Immunotherapeutics buyer in Q4 2024 was UBS Group, an estimated $80.6K added.
  • The largest Scinai Immunotherapeutics seller in Q4 2024 was Aspire Private Capital, an estimated $110 sold.

Based on aggregated 13F filings for Q4 2024.